submit to the journals

Immunotherapy Journal Articles, Videos And Insights

Immunotherapy:FEATURED Articles

flipper_slider

Immunotherapy: Latest Articles

Immunotherapy: INSIGHTS

The touchONCOLOGY website provides a selection of resources to inform clinicians and patients about the latest developments in the field. The following are quick, non peer-reviewed, opinion-based updates addressing current trends and opinion on the most recent advances in the area of oncology:

Meeting Proceedings
Pembrolizumab Plus Axitinib Improves Survival as First-line Treatment in Patients with Renal Cell Carcinoma Katrina Mountfort
Senior Medical Writer, Touch Medical Media, Goring-on-Thames, UK
Meeting Proceedings
ESMO 2018 – Immunotherapy may Become new First-line Treatment in some Metastatic Colorectal Cancers Katrina Mountfort
Senior Medical Writer, Touch Medical Media, Goring-on-Thames, UK
Insight
Realising the Promise of Cell Therapy – The Automated In-house CAR T cell Manufacturing System James Gilbart
Touch Medical Communications, Goring on Thames, UK

Immunotherapy:FEATURED VIDEOS

Editor's choice

Giuseppe Procopio from Fondazione IRCCS Instituto Nazionale dei Tumori in Milan, Italy talks to us about the RESORT trial and limitations of using sorafenib in patients with metastatic renal cell carcinoma after radical resection of metastases. 1. What is the rationale for investigating radical resection of metastases followed by sorafenib in advanced renal cell carcinoma? (0:11) 2. Could you tell us a little about the RESORT study design? (1:15) 3. What were the findings of the study? (1:50) 4. Why do you think sorafenib has no effect on relapse-free survival? (3:17) 5. What will be the next steps in this clinical investigation? (4:06) Speaker disclosures: Giuseppe Procopio serves on the advisory board for Bayer, Bristol-Myers Squibb, Ipsen, Novartis and Pfizer. Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018
Part 1 of 2 – In our interview with Dr Ajjai Alva, he discusses the importance of histology and performance status in selecting patients for high dose interleukin-2 therapy. Filmed at The American Society of Clinical Oncology (ASCO) meeting, 2017

Immunotherapy:Latest Videos

Video List based on Category on Node Page

Latest Videos

Elderly patients are often under-represented in clinical trials and therefore may not receive the necessary treatment. Dr Matti Aapro explains that elderly patients should receive immunotherapy under the same circumstances as younger patients. While they may experience more treatment-related...
We met with Dr Paolo Ascierto at ESMO 2018 to discuss the recent developments in the treatment of advanced melanoma. In this interview with touchONCOLOGY, Dr Ascierto reviews some of the recent trials investigating various immunotherapy combinations, and how survival rates have increased over the...
Giuseppe Procopio from Fondazione IRCCS Instituto Nazionale dei Tumori in Milan, Italy talks to us about the RESORT trial and limitations of using sorafenib in patients with metastatic renal cell carcinoma after radical resection of metastases. 1. What is the rationale for...
Part 2 of 2 - Dr Ajjai Alva explains checkpoint inhibitors and discusses their use in combination with IL-2 for patients who do not respond to checkpoint inhibitors alone. Filmed at The American Society of Clinical Oncology (ASCO) meeting, 2017
Part 1 of 2 – In our interview with Dr Ajjai Alva, he discusses the importance of histology and performance status in selecting patients for high dose interleukin-2 therapy. Filmed at The American Society of Clinical Oncology (ASCO) meeting, 2017
Ahmad Awada, from our editorial board, discusses the current and future developments in immunotherapy.

LATEST TWEETS

Conference Highlights